Study: NCT02012166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0893 200 mg
Description: MK-0893 200 mg administered orally in 240 mL of water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0893 200 mg
Description: MK-0893 200 mg administered orally in 240 mL of water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0893 200 mg
Description: MK-0893 200 mg administered orally in 240 mL of water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0893 1000 mg
Description: MK-0893 1000 mg administered orally in 240 mL of water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0893 1000 mg
Description: MK-0893 1000 mg administered orally in 240 mL of water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0893 1000 mg
Description: MK-0893 1000 mg administered orally in 240 mL of water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo administered orally in 240 mL of water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo administered orally in 240 mL of water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo administered orally in 240 mL of water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo administered orally in 240 mL of water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo administered orally in 240 mL of water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo administered orally in 240 mL of water

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sandostatine®
Description: Sandostatine® is a somatostatin analogue. At 24 and at 72 (Part I) or 120 (Part II) hours postdose, simultaneous infusions of the Sandostatine®, insulin, and glucagon will be administered over a 2-hour period. These compounds are IV compatible and will be combined in one syringe. Intravenous Sandostatine® will be administered at 30 ng/kg/min.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sandostatine®
Description: Sandostatine® is a somatostatin analogue. At 24 and at 72 (Part I) or 120 (Part II) hours postdose, simultaneous infusions of the Sandostatine®, insulin, and glucagon will be administered over a 2-hour period. These compounds are IV compatible and will be combined in one syringe. Intravenous Sandostatine® will be administered at 30 ng/kg/min.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sandostatine®
Description: Sandostatine® is a somatostatin analogue. At 24 and at 72 (Part I) or 120 (Part II) hours postdose, simultaneous infusions of the Sandostatine®, insulin, and glucagon will be administered over a 2-hour period. These compounds are IV compatible and will be combined in one syringe. Intravenous Sandostatine® will be administered at 30 ng/kg/min.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sandostatine®
Description: Sandostatine® is a somatostatin analogue. At 24 and at 72 (Part I) or 120 (Part II) hours postdose, simultaneous infusions of the Sandostatine®, insulin, and glucagon will be administered over a 2-hour period. These compounds are IV compatible and will be combined in one syringe. Intravenous Sandostatine® will be administered at 30 ng/kg/min.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sandostatine®
Description: Sandostatine® is a somatostatin analogue. At 24 and at 72 (Part I) or 120 (Part II) hours postdose, simultaneous infusions of the Sandostatine®, insulin, and glucagon will be administered over a 2-hour period. These compounds are IV compatible and will be combined in one syringe. Intravenous Sandostatine® will be administered at 30 ng/kg/min.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sandostatine®
Description: Sandostatine® is a somatostatin analogue. At 24 and at 72 (Part I) or 120 (Part II) hours postdose, simultaneous infusions of the Sandostatine®, insulin, and glucagon will be administered over a 2-hour period. These compounds are IV compatible and will be combined in one syringe. Intravenous Sandostatine® will be administered at 30 ng/kg/min.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sandostatine®
Description: Sandostatine® is a somatostatin analogue. At 24 and at 72 (Part I) or 120 (Part II) hours postdose, simultaneous infusions of the Sandostatine®, insulin, and glucagon will be administered over a 2-hour period. These compounds are IV compatible and will be combined in one syringe. Intravenous Sandostatine® will be administered at 30 ng/kg/min.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Insulin
Description: At 24 and at 72 (Part I) or 120 (Part II) hours postdose, simultaneous infusions of the Sandostatine®, insulin, and glucagon will be administered over a 2-hour period. These compounds are IV compatible and will be combined in one syringe. Intravenous insulin will be administered at 0.10 milli-international unit (mIU)/kg/min.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Insulin
Description: At 24 and at 72 (Part I) or 120 (Part II) hours postdose, simultaneous infusions of the Sandostatine®, insulin, and glucagon will be administered over a 2-hour period. These compounds are IV compatible and will be combined in one syringe. Intravenous insulin will be administered at 0.10 milli-international unit (mIU)/kg/min.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Insulin
Description: At 24 and at 72 (Part I) or 120 (Part II) hours postdose, simultaneous infusions of the Sandostatine®, insulin, and glucagon will be administered over a 2-hour period. These compounds are IV compatible and will be combined in one syringe. Intravenous insulin will be administered at 0.10 milli-international unit (mIU)/kg/min.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Insulin
Description: At 24 and at 72 (Part I) or 120 (Part II) hours postdose, simultaneous infusions of the Sandostatine®, insulin, and glucagon will be administered over a 2-hour period. These compounds are IV compatible and will be combined in one syringe. Intravenous insulin will be administered at 0.10 milli-international unit (mIU)/kg/min.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Insulin
Description: At 24 and at 72 (Part I) or 120 (Part II) hours postdose, simultaneous infusions of the Sandostatine®, insulin, and glucagon will be administered over a 2-hour period. These compounds are IV compatible and will be combined in one syringe. Intravenous insulin will be administered at 0.10 milli-international unit (mIU)/kg/min.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Insulin
Description: At 24 and at 72 (Part I) or 120 (Part II) hours postdose, simultaneous infusions of the Sandostatine®, insulin, and glucagon will be administered over a 2-hour period. These compounds are IV compatible and will be combined in one syringe. Intravenous insulin will be administered at 0.10 milli-international unit (mIU)/kg/min.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Insulin
Description: At 24 and at 72 (Part I) or 120 (Part II) hours postdose, simultaneous infusions of the Sandostatine®, insulin, and glucagon will be administered over a 2-hour period. These compounds are IV compatible and will be combined in one syringe. Intravenous insulin will be administered at 0.10 milli-international unit (mIU)/kg/min.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Glucagon
Description: At 24 and at 72 (Part I) or 120 (Part II) hours postdose, simultaneous infusions of the Sandostatine®, insulin, and glucagon will be administered over a 2-hour period. These compounds are IV compatible and will be combined in one syringe. Intravenous glucagon will be administered at 3 ng/kg/min.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Glucagon
Description: At 24 and at 72 (Part I) or 120 (Part II) hours postdose, simultaneous infusions of the Sandostatine®, insulin, and glucagon will be administered over a 2-hour period. These compounds are IV compatible and will be combined in one syringe. Intravenous glucagon will be administered at 3 ng/kg/min.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Glucagon
Description: At 24 and at 72 (Part I) or 120 (Part II) hours postdose, simultaneous infusions of the Sandostatine®, insulin, and glucagon will be administered over a 2-hour period. These compounds are IV compatible and will be combined in one syringe. Intravenous glucagon will be administered at 3 ng/kg/min.